- Home
- PRAX vs EPR Comparison
PRAX vs EPR Comparison
Compare PRAX & EPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- EPR
- Stock Information
- Founded
- PRAX 2015
- EPR 1997
- Country
- PRAX United States
- EPR United States
- Employees
- PRAX N/A
- EPR N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- EPR Real Estate Investment Trusts
- Sector
- PRAX Health Care
- EPR Real Estate
- Exchange
- PRAX Nasdaq
- EPR Nasdaq
- Market Cap
- PRAX 4.0B
- EPR 4.4B
- IPO Year
- PRAX 2020
- EPR 1997
- Fundamental
- Price
- PRAX $179.18
- EPR $50.85
- Analyst Decision
- PRAX Strong Buy
- EPR Buy
- Analyst Count
- PRAX 12
- EPR 10
- Target Price
- PRAX $212.42
- EPR $58.19
- AVG Volume (30 Days)
- PRAX 978.5K
- EPR 824.4K
- Earning Date
- PRAX 11-05-2025
- EPR 10-29-2025
- Dividend Yield
- PRAX N/A
- EPR 6.96%
- EPS Growth
- PRAX N/A
- EPR N/A
- EPS
- PRAX N/A
- EPR 2.29
- Revenue
- PRAX $7,463,000.00
- EPR $707,150,000.00
- Revenue This Year
- PRAX N/A
- EPR $4.97
- Revenue Next Year
- PRAX $44.43
- EPR $2.78
- P/E Ratio
- PRAX N/A
- EPR $22.26
- Revenue Growth
- PRAX 364.98
- EPR 3.73
- 52 Week Low
- PRAX $26.70
- EPR $41.75
- 52 Week High
- PRAX $206.71
- EPR $61.24
- Technical
- Relative Strength Index (RSI)
- PRAX 62.04
- EPR 40.80
- Support Level
- PRAX $159.74
- EPR $49.00
- Resistance Level
- PRAX $188.53
- EPR $51.36
- Average True Range (ATR)
- PRAX 13.41
- EPR 1.12
- MACD
- PRAX -5.00
- EPR 0.11
- Stochastic Oscillator
- PRAX 47.30
- EPR 46.16
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About EPR EPR Properties
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.